MapLight Raises $150 M PIPE To Fund CNS Pipeline

MapLight Therapeutics (MPLT) priced a $150 million PIPE, selling 9.2M shares at $11.38 and 4.0M pre-funded warrants at $11.3799, exercisable at $0.0001 with no expiration. Proceeds will fund CNS drug ML-007C-MA, including VISTA Phase 2 in Alzheimer’s disease psychosis and ZEPHYR-2 Phase 3 in schizophrenia. Closing expected Aug. 14, 2026.

Original reporting
Published Aug 13, 2026, 10:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 10:49 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$MPLT
Neutral
medium confidence
Mentioned
$MPLT
Relevance
8/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$MPLTNeutralMed
01

Why it matters

The $150M PIPE increases liquidity and extends funding through 2028, but the fixed issuance at $11.38 introduces dilution overhang that can pressure the stock until investors model the updated capital needs and trial timelines.

02

Market read

Traders can reassess dilution and financing risk ahead of the August 14 close, using the disclosed pricing, share counts, and stated cash runway through 2028.

03

What to watch

The article does not state whether the PIPE includes any investor lockups, resale restrictions, or whether the pre-funded warrants materially change effective dilution versus common issuance.

Relevance 8/10Novelty 8/10Timing: expected close on August 14, 2026

Background

MapLight is advancing CNS programs including an Alzheimer’s disease psychosis Phase 2 study (VISTA) and a schizophrenia Phase 3 registrational study (ZEPHYR-2), with an FDA End-of-Phase 2 meeting planned.

Company-level read

Ticker impact

$MPLTNeutralMedium confidence
Context

MapLight priced a $150M PIPE, issuing 9.2M shares at $11.38 and funding CNS trials including VISTA Phase 2 and ZEPHYR-2 Phase 3.

Expected impact

Likely near-term volatility with a bias to downside from dilution, partially offset by improved funding visibility through 2028.

Evidence & confidence

The article discloses deal size, pricing, share count, and stated cash runway, which directly affects dilution expectations and perceived financing risk.

Market effects

CNS biotech financing conditions may remain active, but PIPE pricing can signal investor selectivity for late-stage trial funding.

No specific regional market linkage beyond US biotech capital markets.

Limited direct global impact; primarily affects MapLight’s capital structure and trial funding.

Counterpoint

If the PIPE price is viewed as reasonable relative to the company’s cash runway and upcoming FDA End-of-Phase 2 milestone, the financing could be interpreted as de-risking rather than dilutive pressure.

Key entities

  • MapLight Therapeutics, Inc.

    Subject of the PIPE financing used to fund ML-007C-MA clinical development and FDA Phase 3 design discussions.

  • ML-007C-MA

    Lead CNS candidate referenced as the primary use of proceeds.

  • VISTA Phase 2 (Alzheimer’s disease psychosis)

    Phase 2 study expected to be advanced with PIPE proceeds.

  • ZEPHYR-2 Phase 3 (schizophrenia)

    Registrational Phase 3 study expected to be advanced with PIPE proceeds.

  • FDA End-of-Phase 2 meeting

    Planned engagement to finalize Phase 3 trial design for schizophrenia.

Related articles

$MPLTMed

MapLight Therapeutics 3Q 2026: EPS ($0.97) — 10-Q Summary

MapLight Therapeutics reported a wider net loss of $51.62M in 3Q 2026, up 75.5% YoY, due to increased R&D and clinical trial expenses. Diluted EPS was ($0.97). The company plans a Phase 3 schizophrenia trial and expects Alzheimer’s disease psychosis trial results in 2H 2027. Cash reserves of $463.4M are expected to last through 2028.

$MPLTHigh

MapLight Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

MapLight Therapeutics, Inc. (MPLT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 MapLight Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update Planning underway for ZEPHYR-2, the confirmatory Phase 3 trial of ML-007C-MA in schizophrenia, with topline results expected in the second half 2027 Enrollment ongoing in

$MPLTMed

MapLight Therapeutics, Inc. (MPLT): Reported positive results from the potentially registrational Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia, supporting advancement into a Phase 3…

MapLight Therapeutics, Inc. (MPLT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Reported positive results from the potentially registrational Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia, supporting advancement into a Phase 3 ZEPHYR-2 trial Continued advancement of ML-007C-MA in ADP, with enrollment ongoing in the Phase 2 VISTA trial and